Ahold NV (ADRNY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most ...

PLIANT THERAPT (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a ...

Zacks.com users have recently been watching Celsius (CELH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Stifel analyst Nathan Jones lowered the firm’s price target on Donaldson (DCI) to $63 from $70 and keeps a Hold rating on the shares. The firm ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: PRA Group (PRAA Quick Quote PRAA - Free Report) : This global financial and business services company in the Americas, ...